Using bespoke technologies could address market barriers in the small-scale livestock sector

Small-scale farming account for a large part of the farming industry in low and middle-income countries. Despite small-scale livestock producers’ key role in the agricultural industry, existing market barriers and constraints hinder their opportunities to access high-quality animal health products and services.

Different market barriers are present across the entire value chain and deter animal health companies from investing in these markets. Some of the major barriers identified are lack of reliable market information and market entry, proper distribution mechanisms of products, scattered demand, or service provision.

As part of GALVmed’s Strategy2030, we are proposing a dedicated focus on collaborating with different partners and veterinary authorities to develop tailored technology platforms to bridge the gaps and overcome these market barriers. This suggested platform approach marks a significant change in GALVmed commercial development strategy. Whereas previously, a single commercial partner would spearhead a single initiative, the new approach will enable the entire industry to plug into a benefit from a single platform. By collectively addressing the key constraints facing the entire animal health value chain, the proposed platforms have the potential to deliver a comprehensive, financially sustainable solution that will unlock new opportunities for growth in the animal health industry.

With this proposed approach, the end goal is to significantly increase investment in the small-scale sector by the animal health industry, and improve market supply and adoption of key animal health products that will grant better opportunities to small-scale producers to protect their livestock and secure their livelihoods.

This blog was written as part of the campaign “Barriers to Animal Health Markets”

GALVmed discusses impact

Impact is an important topic for any philanthropic organisation and GALVmed is putting this topic front and centre of our agenda for 2022. The primary reason is that we are in the process of finalising and beginning to implement our ten-year strategy, and it is vitally important that we integrate the lessons we have learned so far and align on the topic of impact.

To kickstart this process, three workshops were held over the end of January and beginning of February 2022 with the aim to provide a common, organisational understanding of impact. We took a look at our record of impact and discussed some of the associated key lessons learned from the three main programmes GALVmed has delivered to date, namely the first and second Protecting Livestock, Saving Human Life programmes (PLSHL 1 and PLSHL 2), and the Veterinary Innovations Transforming Animal Health and Livelihoods programme (VITAL). These workshops constituted the first phase of a collective look at impact within the organisation.

A second phase is being led by the evaluation team, which operates under the Commercial Development and Impact department (CD&I) at GALVmed. Lasting eight weeks, the primary purpose is to collate further data, present findings to our donors and board, and most importantly, to implement actionable findings into the Commercial Development, Research and Development, Evaluation, and Enabling Environment programmes under the new strategy.

The key activities include taking lessons learned from previous programmes of work and considering the implications for new GALVmed projects and programmes, creating a theory of change for GALVmed at an organisational level, in which the GALVmed mission is clearly stated and pathways to impact explained, and linking impact to GALVmed’s overall assessment of organisational performance. Through this process we intend to identify our potential for impact in the new strategy as well as the key levers and drivers for change.

This blog was written by Katharine Tjasink